Balancing efficacy and safety of JAK inhibitors in myelofibrosis

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 290-291

  Passamonti, Francesco ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIALS AS TOPIC; HUMANS; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894259896     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.022     Document Type: Editorial

References (6)

1. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
2. Passamonti F., Maffioli M., Caramazza D., Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget 2011, 2:485-490.
3. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013.
4. Cervantes F., Vannucchi A.M., Kiladjian J.J., Al-Ali H.K., Sirulnik A., Stalbovskaya V., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013.
5. Pardanani A., Harrison C., Cortes J., Cervantes F., Mesa R., Milligan D., et al. Results of a randomized, double-blind placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor Fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013, 122:393.
6. Pardanani A., Laborde R.R., Lasho T.L., Finke C., Begna K., Al-Kali A., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013, 27:1322-1327.